BeiGene denies AbbVie's accusation of "stealing trade secrets": will launch a firm defense and development projects will not be interrupted as a result
楚一帆
发表于 5 天前
128
0
0
On September 12th, the A-share price of BeiGene (SH688235, stock price 144.01 yuan, market value 198.44 billion yuan) fell sharply by 10.61%.
On the afternoon of the 12th, BeiGene told the Daily Economic News reporter that the company has recently learned that AbbVie has filed a lawsuit against the company, claiming that BeiGene has stolen its trade secrets for the Bruton's tyrosine kinase (BTK) degradation agent project, which includes the compound BGB-16673 independently discovered by BeiGene researchers through years of innovative research.
According to BeiGene's 2024 interim report, BGB-16673 is an investigational chimeric degradation activating compound (CDAC) targeting BTK. On August 27th, BeiGene announced that the FDA has granted the drug fast track status for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously received at least two lines of treatment, including BTK inhibitors and BCL2 inhibitors.
In addition, the company also expects in its 2024 interim report that the first trial of BGB-16673 for the treatment of R/R and CLL/SLL will enroll the first subject in the fourth quarter of 2024 or the first quarter of 2025.
BeiGene told reporters that the company will vigorously defend itself against the allegations made by AbbVie. The company denies this accusation and will firmly defend its intellectual property rights against the lawsuit. BeiGene believes that the lawsuit intends to hinder the development process of BGB-16673, which is currently the fastest progressing BTK degradation agent in clinical development. BeiGene had already applied for a patent for BGB-16673 several years before AbbVie first applied for a BTK degradation agent patent. BeiGene firmly believes that its research and development projects adhere to the principle of integrity.
BeiGene's focus on advancing the BGB-16673 development project will not be interrupted by this lawsuit. We are currently carefully reviewing AbbVie's complaint and will respond appropriately through legal procedures. In addition, this lawsuit will not affect our ability to serve patients or carry out operations, "BeiGene said.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- After a series of twists and turns, the core product of Baekje Shenzhou, Baekze An, has become the second domestically produced PD-1 approved in the United States
- BeiGene: Net profit for 2023 is approximately -6.716 billion yuan
- BeiGene: Chief Financial Officer Wang Aijun will resign on July 19th
- Beike responds to land acquisition in Xi'an: a 1+2 model for diversified cooperation and non independent development projects
- Company Review | BeiGene has suffered continuous losses in the past 7 years, and its stock price is under pressure. Can the new CFO bring a turning point?
- More than 40% reduction in losses in the first half of the year, but multiple peers have achieved profits. BeiGene is facing increasing peer pressure
- AbbVie sues for infringement again, BeiGene denies allegations: this move is intended to prevent project development
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
-
【世界市場】1、納指は0.04%、ダウは0.70%、スタンダードは0.19%下落した。2、英偉達は2%超上昇し、美光科技の株価は10%超上昇した。3、ナスダック中国の金龍指数は2.80%、蔚来は5%近く下落した。4、国際原油価格は ...
- 虚空一粒沙2017
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
世界的な整形外科大手のシュレックはこのほど、ニューラルテクノロジー会社のNico Corporationの買収を完了したと発表した。紹介によると、Nicoは私営会社で、腫瘍と脳内出血(ICH)手術のための系統的な低侵襲手術 ...
- 就放荡不羁就h
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
AP通信9月27日、インテルは今月中旬に発表された重大な業務調整に加え、近日中にクアルコムに買収合併される可能性があるとの情報を伝えていることを明らかにした。 しかし、ウォール街のほとんどのアナリストは、 ...
- 什么大师特
- 前天 16:13
- 支持
- 反对
- 回复
- 收藏
-
9月26日、Meta Platformsは巨額の資金を投じてスターを招待していることを明らかにした。Metaは水曜日、俳優のオスカー・フィーナ(Awkwafina)、ジョン・セナ(John Cena)、ジュディ・デンチ(Judi Dench)、クリ ...
- hecgdge4
- 3 天前
- 支持
- 反对
- 回复
- 收藏